The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / How Immunosuppression May Affect COVID-19 Vaccine Response

How Immunosuppression May Affect COVID-19 Vaccine Response

June 13, 2021 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response.

You Might Also Like
  • Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly
  • Synthetic DMARDs May Blunt Pneumococcal Vaccine Response in Systemic Sclerosis
Explore This Issue
June 2021
Also By This Author
  • ‘Battle for Health Justice’: Dr. Alakija Addresses Global Rheumatology Inequities

Rheumatologists should use caution in interpreting early reports, while continuing to encourage their patients to get vaccinated and take appropriate preventative measures.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Immunosuppressed Patients

The large trials used to test the efficacy and safety of the SARS-CoV-2 messenger RNA (mRNA) vaccines largely excluded patients with rheumatic diseases, as well as people on immunosuppressives for other indications. Although this made sense in terms of vaccine development, it left open questions about the efficacy and safety of the vaccines for people taking immunosuppressive therapies. Such individuals may potentially be at risk of a poor response to one or more of these vaccines, in terms of decreased efficacy or due to potential side effects, such as disease flare.

Dr. Segev

Dr. Segev

Dorry L. Segev, MD, PhD, a professor of surgery and epidemiology at Johns Hopkins School of Medicine, Baltimore, is an investigator on two ongoing trials focused on these responses. In one trial, researchers are studying immunosuppressed solid organ transplant recipients, and in another they are looking at vaccine responses in people with chronic conditions that require immunosuppression, including rheumatic diseases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Because of the very nature of immunosuppressive medications, researchers have held concerns about whether people taking such medications will form an adequate long-term immune response when vaccinated. According to Dr. Segev, to respond effectively to a vaccine, the immune system must successfully activate certain pathways involving antigen presentation, potentially evoking both a B cell and T cell response. “Medications that suppress the immune system might suppress certain parts of that pathway, and some might suppress parts of it more than others,” he says.

To provide guidance to rheumatologists with respect to the new COVID-19 vaccines, the ACR convened a COVID-19 Vaccine Guidance Task Force, a branch of the broader ACR vaccine guideline effort. To make their recommendations, members of the task force surveyed the available literature on COVID-19 and COVID-19 vaccines, as well as indirect data on the response to other types of vaccines in patients with rheumatic conditions.1

One task force member, Cassandra Calabrese, DO, a rheumatologist and infectious disease specialist who is an associate staff member at the Cleveland Clinic, Ohio, notes that although people often group immunosuppressed patients together, patients receiving different specific types and degrees of immunosuppression may respond quite differently in terms of vaccine reactogenicity.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For example, a 2014 meta-analysis concluded patients receiving rituximab displayed a poorer humoral response to both the influenza and pneumococcal vaccines, but patients on tumor necrosis factor (TNF) inhibitors did not show reduced response to either vaccine.2

Making use of the data available, the task force made specific recommendations about vaccination timing and immunomodulatory therapy for specific treatments. These included scheduling the vaccine to be given about four weeks prior to the next scheduled rituximab cycle and delaying rituximab two to four weeks after the second vaccine dose, if patient circumstances permit.1

The committee has released an updated version of its vaccine guidance, based on the initial data about vaccine response that have begun to accrue.3 This version provides updated recommendations on timing considerations for mycophenolate mofetil, methotrexate, acetaminophen and non-steroidal anti-inflammatory drugs. (The full second version of the paper is expected to be published in Arthritis & Rheumatology.)

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Safety Tagged With: COVID-19, immunosuppression, vaccinationIssue: June 2021

You Might Also Like:
  • Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly
  • Synthetic DMARDs May Blunt Pneumococcal Vaccine Response in Systemic Sclerosis
  • More Info on the J&J COVID-19 Vaccine Thrombosis Scare

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)